Shares Magazine
$315.50+2.00 (+0.64%)24 Mar 2025, 19:13
Jump to:
Amgen INC Fundamentals
| Company Name | Amgen INC | Last Updated | 2025-03-24 |
|---|---|---|---|
| Industry | Drug Manufacturers - General | Sector | Healthcare |
| Shares in Issue | 537.205 m | Market Cap | $169.49 bn |
| PE Ratio | 41.47 | Dividend per Share | $9.00 |
| Dividend Yield | 2.91 | Dividend Cover | 0.84 |
| EPS | $7.56 | EPS Growth (%) | -0.39 |
| PEG | 1.06 | DPS Growth (%) | 0.0563 |
| Debt Ratio | 0.6544 | Debt Equity Ratio | 9.6221 |
| Asset Equity Ratio | 15.6269 | Cash Equity Ratio | 2.0373 |
| Quick Ratio | 0.8431 | Current Ratio | 1.26 |
| Price To Book Value | 28.6533 | ROCE | 0 |
Amgen INC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Interim | 2025-05-16 | 2025-06-06 | USD | 2.3800 | |
| Interim | 2025-02-14 | 2025-03-07 | USD | 2.3800 | |
| Prelim | 2024-11-18 | 2024-12-09 | USD | 2.2500 | |
| Interim | 2024-08-16 | 2024-09-06 | USD | 2.2500 | |
| Interim | 2024-05-16 | 2024-06-07 | USD | 2.2500 | |
| Interim | 2024-02-15 | 2024-03-07 | USD | 2.2500 | |
| Prelim | 2023-11-16 | 2023-12-08 | USD | 2.1300 | |
| Interim | 2023-08-17 | 2023-09-08 | USD | 2.1300 | |
| Interim | 2023-05-17 | 2023-06-08 | USD | 2.1300 | |
| Interim | 2023-02-14 | 2023-03-08 | USD | 2.1300 | |
| Prelim | 2022-11-16 | 2022-12-08 | USD | 1.9400 | |
| Interim | 2022-08-17 | 2022-09-08 | USD | 1.9400 | |
| Interim | 2022-05-16 | 2022-06-08 | USD | 1.9400 |
Amgen INC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $6.54 bn | $5.94 bn | $5.43 bn |
| Intangible Assets | $46.34 bn | $51.27 bn | $31.61 bn |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $62.81 bn | $66.82 bn | $42.94 bn |
| Stocks | $7.00 bn | $9.52 bn | $4.93 bn |
| Debtors | 0 | 0 | 0 |
| Cash & Equivalents | $11.97 bn | $10.94 bn | $9.30 bn |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $91.84 bn | $97.15 bn | $65.12 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $23.10 bn | $18.39 bn | $15.69 bn |
| Creditors after 1 year | $62.86 bn | $72.53 bn | $45.77 bn |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $85.96 bn | $90.92 bn | $61.46 bn |
| Net assets | $5.88 bn | $6.23 bn | $3.66 bn |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $33.53 bn | $33.07 bn | $32.51 bn |
| Share Premium | 0 | 0 | 0 |
| Profit / Loss | $4.61 bn | $7.86 bn | $7.35 bn |
| Other Equity | $5.88 bn | $6.23 bn | $3.66 bn |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $5.88 bn | $6.23 bn | $3.66 bn |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.91 | $0.91 | $0.91 |
| Debt-to-Equity | $9.62 | $10.14 | $10.20 |
| Assets / Equity | 15.6269 | 15.6269 | 15.6269 |
| Cash / Equity | 2.0373 | 2.0373 | 2.0373 |
| EPS | $7.62 | $12.56 | $12.18 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $11.49 bn | $8.47 bn | $9.72 bn |
| Cashflow before financing | $2.08 bn | $29.52 bn | $5.68 bn |
| Increase in Cash | $1.03 bn | $3.31 bn | -$360.00 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $33.42 bn | $28.19 bn | $26.32 bn |
| Cost of sales | $12.86 bn | $8.45 bn | $6.41 bn |
| Gross Profit | $20.57 bn | $19.74 bn | $19.92 bn |
| Operating Profit | $7.26 bn | $7.90 bn | $9.57 bn |
| Pre-Tax profit | $4.61 bn | $7.86 bn | $7.35 bn |
Amgen INC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio. |
| Latest Interim Date | 6 Aug 2024 |
| Latest Fiscal Year End Date | 4 Feb 2025 |
Amgen INC Directors
| Appointed | Name | Position |
|---|---|---|
| 2018-05-03 | Mr. Anthony C. Hooper | EVP, Global Commercial Ops. |
| 2004-12-31 | Dr. Beth C. Seidenberg,M.D. | Sr VP, Dev & Chief Medical Ofc |
| 2014-06-30 | Michael A Kelly | Acting CFO |
| 2024-05-31 | Ms. Amy E. Miles | Director |
| 2012-08-01 | Ms. Anna S. Richo | SVP & CCO |
| 2024-11-04 | Mr. Charles M. Holley, Jr | Director |
| 2015-04-25 | Mr. David J. Scott | SVP, Gen. Counsel & Secy. |
| 2005-04-26 | Mr. Edward V. Fritzky | Director |
| 2019-05-03 | Mr. Frank C. Herringer | Director |
| 2011-04-25 | Mr. Frederick W. Gluck | Director |
| 2019-11-25 | Mr. David W. Meline | EVP & CFO |
| 2007-06-04 | Dr. Dennis M. Fenton,PhD | Executive V.P., Operations |
| 2006-03-15 | Dr. Donald B Rice | Director |
| 2024-05-31 | Ms. Ellen J. Kullman | Director |
| 2020-05-05 | Mr. Fred Hassan | Director |
| 2013-04-26 | Admiral J. Paul Reason | Director |
| 2014-04-25 | Dr. Gilbert S. Omenn,M.D.,PhD | Director |
| 2006-04-03 | Hassan Dayem,PhD | Sr. V.P. & Chief Info. Officer |
| 2011-04-25 | Mr. Jerry D. Choate | Director |
| 2017-05-01 | Ms. Judith C. Pelham | Director |
| 2004-11-12 | Joseph P. Miletich | Sr VP Rsch & Preclinical Dev |
| 2012-10-26 | Mr. Kevin W. Sharer | Director |
| 2013-04-26 | Mr. Leonard D. Schaeffer | Director |
| 2006-10-31 | Mr. Richard D. Nanula | Exe VP & CFO |
| 2004-05-13 | Ms. Patricia C. Sueltz | Director |
| 2023-05-19 | Dr. Robert Sanders Williams, M.D. | Director |
| 2024-05-31 | Mr. Robert A. Eckert | Director |
| 2025-03-17 | Mr. Robert A. Bradway | Director, Chairman, CEO and President |
| 2012-02-02 | Dr. Roger M. Perlmutter,M.D.,PhD | EVP, Research & Development |
| 2023-05-19 | Dr. Ronald D. Sugar | Director |
| 2005-03-15 | Mr. Timothy O. Martin | VP, Control Plng & CAO |
| 2004-01-27 | Mr. Steven M. Odre | Sr. VP, Gen. Counsel & Secy. |
| 2017-05-01 | Mr. Brian Mcnamee | EVP |
| 2016-05-03 | Dr. Vance D. Coffman | Director |
| 2004-12-13 | Dr. Willard H. Dere, M.D. | Sr. V.P., Global Dev & CMO |
| 2006-05-09 | Mr. Franklin P. Johnson,Jr | Director |
| 2018-04-27 | Dr. David Baltimore, PhD | Director |
| 2012-05-03 | Mr. David William Beier, J.D. | SVP, Global Govt Affairs |
| 2012-07-27 | Dr. Fabrizio Bonanni | EVP, Operations |
| 2017-05-01 | Mr. Frank J. Biondi, Jr | Director |
| 2010-04-28 | Mr. George J. Morrow | Exe VP, Global Commercial Ops |
| 2020-05-05 | Dr. Rebecca M. Henderson,PhD | Director |
| 2010-12-08 | Mr. Thomas J. Flanagan | Sr VP & CIO |
| 2004-03-15 | Mr. Steven B. Lazarus | Director |
| 2018-04-27 | De Carbonnel Francois | Director |
| 2024-05-31 | Professor Dr. Tyler E. Jacks, PhD | Director |
| 2021-04-30 | Mr. David A. Piacquad | SVP, Business Development |
| 2025-03-17 | Mr. Jonathan P. Graham | EVP & Gen. Counsel & Secy. |
| 2016-05-03 | Mr. Madhu Balachandran | EVP, Operations |
| 2014-05-21 | Mr. Thomas Dittrich | VP, Finance & CAO |
| 2013-10-28 | Mr. Jonathan M. Peacock | EVP & CFO |
| 2024-05-31 | Mr. Greg C. Garland | Director |
| 2018-07-16 | Dr. Sean E. Harper | EVP, Research & Development |
| 2022-03-01 | Ms. Lori A Johnston | EVP, HR |
| 2020-05-05 | Ms. Cynthia M. Patton | SVP & CCO |
| 2016-05-03 | Dr. Stuart A. Tross, PhD | SVP, Human Resources |
| 2025-03-17 | Mr. Murdo Gordon | EVP, Global Commercial Ops |
| 2024-05-07 | Dr. James E. Bradner, M.D. | EVP, R&D, & Chief Sci. Officer |
| 2017-05-01 | Ms. Annette L. Such | VP, Finance and CAO |
| 2025-03-17 | Mr. Esteban Santos | EVP, Operations |
| 2024-05-31 | Dr. Wanda M. Austin | Director |
| 2024-05-31 | Dr. Brian J. Druker, M.D. | Director |
| 2025-03-17 | Dr. David M. Reese, M.D. | EVP & Chief Technology Officer |
| 2025-03-17 | Mr. Peter H. Griffith | EVP & CFO |
| 2025-03-17 | Ms. Nancy A. Grygiel | SVP & CCO |
| 2023-05-05 | Ms. Linda H. Louie | VP, Finance & CAO |
| 2025-03-17 | Ms. Rachna Khosla | SVP, Business Development |
| 2025-03-17 | Mr. Derek Miller | SVP, Human Resources |
| 2024-11-04 | Mr. Michael V. Drake | Director |
| 2025-03-17 | Mr. Matthew C. Busch | VP, Finance & CAO |
| 2024-05-31 | Ms. Mary E. Klotman | Director |
Amgen INC Contact Details
| Company Name | Amgen Inc |
|---|---|
| Address | One Amgen Center Drive, Thousand Oaks, 91320-1799 |
| Telephone | +1 805 4471060 |
| Website | https://www.amgen.com |
Amgen INC Advisors
| Auditor | Ernst & Young LLP |
|---|
| Auditor | Ernst & Young LLP |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Pershing Square Holdings LTD | 3,906.00 | 3.94 |
| Asos PLC | 312.40 | 3.51 |
| Baillie Gifford Us Growth Trust PLC | 237.00 | 3.49 |
| Bellway PLC | 2,412.00 | 3.34 |
| Wizz Air Holdings PLC | 1,705.00 | 3.33 |
| Polar Capital Technology Trust PLC | 317.00 | 3.26 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Energean PLC | 815.50 | -6.53 |
| Oxford Nanopore Technologies PLC | 104.30 | -6.46 |
| Aston Martin Lagonda Global Holdings PLC | 72.75 | -4.65 |
| Harbour Energy PLC | 195.45 | -4.47 |
| Vodafone Group PLC | 72.00 | -4.43 |
| Discoverie Group PLC | 572.00 | -3.70 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.